Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Ki Byung Song

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5422-5481; OpenAlex author ID A5011956644, A5123504008. Sources: OpenAlex.

Their work

Papers
61 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
96
Papers, trials and grants by year

2013: 1 paper · 2014: 3 papers · 2015: 1 paper · 2016: 1 paper · 2017: 4 papers · 2018: 4 papers · 2019: 7 papers · 2020: 9 papers · 2021: 8 papers · 2022: 7 papers · 2023: 5 papers · 2024: 5 papers · 2025: 2 papers · 2026: 4 papers

Papers 50 of 61

  1. Minimally invasive vs. open-extended distal pancreatectomy with multi-organ resection: postoperative and oncological outcomes for left-sided pancreatic ductal … Co-author DOI 10.1007/s00464-025-12452-3↗
  2. Differentiating large-duct pancreatic ductal adenocarcinoma from malignant intraductal papillary mucinous neoplasm: MRI characteristics and diagnostic implicat… Co-author DOI 10.1016/j.ejrad.2026.112735↗
  3. Clinical outcomes of completing total pancreatectomy for isolated recurrence of pancreatic ductal adenocarcinoma in the remnant pancreas after initial pancreat… Co-author DOI 10.1016/j.surg.2026.110088↗
  4. Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Tri… Co-author DOI 10.1245/s10434-026-19762-3↗
  5. Applicability of current nodal staging system for resected pancreatic cancer after neoadjuvant therapy: a retrospective study. Co-author DOI 10.1016/j.hpb.2025.04.011↗
  6. Oncological outcomes of palliative minimally invasive distal pancreatectomy for unexpected metastatic pancreatic ductal adenocarcinoma: A single-center experie… Co-author DOI 10.1016/j.surg.2025.109331↗
  7. Computed tomography-based vascular burden index as a predictor of vascular resection and pathological vascular invasion in pancreatic cancer with neo-adjuvant … Co-author DOI 10.1016/j.ejso.2024.108494↗
  8. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
  9. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000001389↗
  10. Prognostic model for resected borderline and locally advanced pancreatic cancer after neoadjuvant chemotherapy. Co-author DOI 10.1097/js9.0000000000001927↗
  11. Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4143/crt.2023.977↗
  12. Effect of resection margin status on recurrence pattern and survival in distal pancreatectomy for left-sided pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.1272↗
  13. Robotic versus laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: A propensity score-matched analysis. Co-author DOI 10.1016/j.hbpd.2022.06.001↗
  14. Outcomes of Distal Pancreatectomy With Celiac Axis Resection for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002218↗
  15. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Co-author DOI 10.4143/crt.2022.409↗
  16. Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Dam… Co-author DOI 10.4143/crt.2023.452↗
  17. Endoplasmic stress-inducing variants in CPB1 and CPA1 and risk of pancreatic cancer: A case-control study and meta-analysis. Co-author DOI 10.1002/ijc.33883↗
  18. The impact of preoperative EUS-FNA for distal resectable pancreatic cancer: Is it really effective enough to take risks? Co-author DOI 10.1007/s00464-021-08627-3↗
  19. Preoperative data-based deep learning model for predicting postoperative survival in pancreatic cancer patients. Co-author DOI 10.1016/j.ijsu.2022.106851↗
  20. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221097190↗
  21. Predictive Performance of Current Nodal Staging Systems in Various Categories of Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10641-7↗
  22. Korean Surgical Practice Guideline for Pancreatic Cancer 2022: A summary of evidence-based surgical approaches Co-author DOI 10.14701/ahbps.22-009↗
  23. Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfron… Co-author DOI 10.21037/gs-22-304↗
  24. A comparison of minimally invasive vs open distal pancreatectomy for resectable pancreatic ductal adenocarcinoma: Propensity score matching analysis. Co-author DOI 10.1002/jhbp.853↗
  25. Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-020-80383-1↗
  26. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Co-author DOI 10.1093/bjs/znab229↗
  27. Clinical Outcome of RAMPS for Left-Sided Pancreatic Ductal Adenocarcinoma: A Comparison of Anterior RAMPS versus Posterior RAMPS for Patients without Periadren… Co-author DOI 10.3390/biomedicines9101291↗
  28. Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker… Co-author DOI 10.3390/biomedicines9111599↗
  29. Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location. Co-author DOI 10.3390/biomedicines9111706↗
  30. Usefulness of Inflammation-Based Prognostic Scores in Patients with Surgically Treated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm10245784↗
  31. Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. First author DOI 10.4240/wjgs.v13.i11.1423↗
  32. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2019.10.036↗
  33. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… Co-author DOI 10.1038/s41416-020-0867-x↗
  34. The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay. Co-author DOI 10.1038/s41598-020-68703-x↗
  35. Arterial resection during pancreatectomy for pancreatic ductal adenocarcinoma with arterial invasion: A single-center experience with 109 patients. Co-author DOI 10.1097/md.0000000000022115↗
  36. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of … Co-author DOI 10.1148/radiol.2020200281↗
  37. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835920953294↗
  38. Comparison of Minimally Invasive Versus Open Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Matching Analysis. First author DOI 10.3390/cancers12040982↗
  39. Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderli… Co-author DOI 10.3390/jcm9051477↗
  40. Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm9061953↗
  41. Management of isolated recurrence after surgery for pancreatic adenocarcinoma. First author DOI 10.1002/bjs.11144↗
  42. Prognostic value of adjacent organ resection in patients with left-sided pancreatic ductal adenocarcinoma following distal pancreatectomy. Co-author DOI 10.1002/jhbp.627↗
  43. Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic D… Co-author DOI 10.1097/mpa.0000000000001255↗
  44. Stereotactic body radiation therapy for locally advanced pancreatic cancer. Co-author DOI 10.1371/journal.pone.0214970↗
  45. Validation of the eighth edition of the American Joint Committee on Cancer staging system and proposal of an improved staging system for pancreatic ductal aden… Co-author DOI 10.14701/ahbps.2019.23.1.46↗
  46. Prognostic Value of Adjuvant Chemotherapy Following Pancreaticoduodenectomy in Elderly Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13206↗
  47. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Canc… Co-author DOI 10.3390/cancers11030278↗
  48. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Co-author DOI 10.1007/s10637-017-0497-1↗
  49. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Co-author DOI 10.1007/s10637-018-0598-5↗
  50. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single-center experience with 2,029 patients. Co-author DOI 10.1016/j.surg.2018.04.017↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dae Wook Hwang · 51 shared papers, 2014–2026 · strength 7.00
  2. Song Cheol Kim · 53 shared papers, 2013–2026 · strength 6.42
  3. Woohyung Lee · 30 shared papers, 2020–2026 · strength 4.71
  4. Yejong Park · 28 shared papers, 2019–2026 · strength 4.53
  5. Eunsung Jun · 17 shared papers, 2017–2026 · strength 2.73
  6. Changhoon Yoo · 18 shared papers, 2017–2026 · strength 2.10
  7. Kyu‐pyo Kim · 18 shared papers, 2014–2026 · strength 2.02
  8. Baek‐Yeol Ryoo · 16 shared papers, 2017–2026 · strength 1.87
  9. Jaewoo Kwon · 15 shared papers, 2019–2023 · strength 1.78
  10. Min Kyu Sung · 8 shared papers, 2021–2025 · strength 1.50
  11. Tae Jun Song · 13 shared papers, 2017–2026 · strength 1.47
  12. Bong Jun Kwak · 10 shared papers, 2014–2024 · strength 1.44
  13. Sarang Hong · 10 shared papers, 2019–2023 · strength 1.22
  14. Sang Soo Lee · 13 shared papers, 2014–2024 · strength 1.18
  15. Jin‐hong Park · 11 shared papers, 2014–2026 · strength 1.14
  16. Do Hyun Park · 11 shared papers, 2017–2024 · strength 1.14
  17. Seung‐Mo Hong · 11 shared papers, 2013–2024 · strength 0.99
  18. Dong Wan Seo · 10 shared papers, 2017–2024 · strength 0.98
  19. Seung Soo Lee · 6 shared papers, 2018–2026 · strength 0.95
  20. Sang Hyun Shin · 12 shared papers, 2013–2020 · strength 0.90
  21. Dongwook Oh · 5 shared papers, 2022–2026 · strength 0.81
  22. Jae Ho Byun · 5 shared papers, 2018–2026 · strength 0.70
  23. Dakyum Shin · 5 shared papers, 2020–2023 · strength 0.69
  24. Hyoung Jung Kim · 5 shared papers, 2017–2024 · strength 0.59
  25. Inkeun Park · 3 shared papers, 2024–2026 · strength 0.58

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.